Dividend investing remains a cornerstone of long-term wealth building, with payouts historically accounting for nearly a third of the S&P 500’s total returns. Yet the dividend universe offers far more variety than simply choosing between high-yield and low-yield names. Three companies showcase fundamentally different approaches to using dividends as part of an overall investment strategy: one prioritizes immediate income, another balances steady payouts with capital appreciation, and a third treats dividends as the bonus rather than the primary thesis.
Understanding these distinctions reveals why investors with different goals might select different dividend payers despite all three representing quality businesses committed to shareholder returns.
Realty Income: The Monthly Income Machine
Realty Income has built its identity around one simple proposition: provide investors with consistent monthly cash flow through a diversified portfolio of commercial real estate. Since 1965, the company has cultivated a reputation for reliability by operating a broad retail portfolio spanning dollar stores, automotive repair shops, casual dining establishments, and numerous other retail categories.
That diversification matters profoundly. Rather than concentrating risk in a single retail niche, Realty Income’s broad approach spreads exposure across multiple consumer spending categories. The company’s use of triple-net leases further protects investor interests by shifting property-level operating expenses—maintenance, taxes, insurance—to the tenants themselves.
The dividend yield of 5.86% dramatically exceeds the market average, making Realty Income particularly attractive for investors prioritizing immediate passive income. The company’s recent expansion into Western Europe, now generating approximately 15% of annualized contractual rent, suggests growth potential beyond the current income stream. For income-focused investors, Realty Income represents the most straightforward approach: substantial current yield backed by a durable business model.
Philip Morris International: The Dividend Growth Story With Capital Appreciation
Philip Morris has navigated a challenging industry landscape by actively reinventing its product portfolio. The tobacco sector historically offered investors both recession resistance and income, yet ethical concerns and regulatory headwinds created genuine uncertainty about long-term viability. Rather than defending tradition, Philip Morris pivoted toward reduced-risk alternatives.
That pivot has proved remarkably successful. Smoke-free products—oral tobacco pouches and IQOS heat-not-burn systems—now represent 42% of net revenue and are growing rapidly. Total net revenue jumped 10.4% year over year to $11.2 billion, driven primarily by this transition toward lower-risk product alternatives.
The stock has delivered 88% returns over the past five years while consistently raising its dividend for 17 consecutive years. The current yield of 3.03% lags Realty Income’s payout, but the combination of dividend growth and capital appreciation creates a fundamentally different return profile. For investors comfortable with transformation stories, Philip Morris offers both income and the potential for meaningful capital gains as the company continues pivoting away from traditional cigarettes.
Eli Lilly: The Growth Story That Also Pays Dividends
Eli Lilly approaches dividends from a different angle entirely. The pharmaceutical company’s primary investment thesis centers on exceptional growth from its diabetes and weight-loss franchises—Mounjaro and Zepbound—combined with an impressive pipeline of next-generation candidates. Second-quarter results exemplified this growth trajectory: revenue climbed 48% year over year to $23 billion while adjusted earnings per share rose 33% to $8.38.
The dividend yield of just 0.58% reflects the market’s valuation of the stock—a company trading on growth expectations rather than current income. Yet the dividend itself tells an important story: it has more than doubled over the past five years despite modest current yields. That trajectory suggests management confidence in the company’s ability to fund increasingly generous payouts from growing earnings.
Eli Lilly’s pipeline strengthens the case for long-term dividend sustainability. Next-generation candidates like retatrutide show compelling clinical results, and Mounjaro’s recent approval for reducing cardiovascular risk in type 2 diabetes patients signals multiple expansion opportunities. For investors prioritizing long-term growth paired with an emerging dividend stream, Eli Lilly represents a different category entirely from traditional income stocks.
